Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis
In this RCT, patients with ANCA-associated vasculitis who achieved complete remission after a cyclophosphamide-glucocorticoid regimen were randomly assigned to receive intermittent rituximab (days 0 and 14 and at months 6, 12, and 18) or daily azathioprine until month 22. Major relapse was less common in the rituximab arm than the azathioprine arm (5% vs 29%) with a hazard ratio for relapse of 6.61; 95% confidence interval, 1.56 to 27.96; P=0.002). There were no differences in adverse events between arms.
:
Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis
Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes
High-Efficiency Postdilution Online Hemodiafiltration Reduces All-Cause Mortality in Hemodialysis Patients
Source: Nephrology Now - Category: Urology & Nephrology Authors: Nephrology Now editors Tags: Vasculitis Source Type: research
More News: Cardiology | Diabetes | Diabetes Type 2 | Dialysis | Endocrinology | Heart | Hemodiafiltration | Hemodialysis | Rituxan | Tekturna | Urology & Nephrology | Vasculitis